Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Geert‐Jan Creemers"'
Autor:
Jonathan E. Knikman, Qinglian Zhai, Carin A. T. C. Lunenburg, Linda M. Henricks, Stefan Böhringer, Maaike van der Lee, Femke M. de Man, Steven M. Offer, Shikshya Shrestha, Geert-Jan Creemers, Arnold Baars, Vincent O. Dezentjé, Alexander L. T. Imholz, Frank J. F. Jeurissen, Johanna E. A. Portielje, Rob L. H. Jansen, Paul Hamberg, Helga J. Droogendijk, Miriam Koopman, Peter Nieboer, Marlène H. W. van de Poel, Caroline M. P. W. Mandigers, Ron H. N. van Schaik, Hans Gelderblom, Ron H. J. Mathijssen, Jan H. M. Schellens, Annemieke Cats, Henk-Jan Guchelaar, Jesse J. Swen
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-11 (2024)
Abstract Background The Alpe-DPD study (NCT02324452) demonstrated that prospective genotyping and dose-individualization using four alleles in DPYD (DPYD*2A/rs3918290, c.1236G > A/rs75017182, c.2846A > T/rs67376798 and c.1679 T > G/rs56038477) can mi
Externí odkaz:
https://doaj.org/article/b16be71c28a348628ff01bad41681526
Autor:
Charlotte I. Stroes, Sybren L. Meijer, Geert-Jan Creemers, Gerrit K.J. Hooijer, Nadia Haj Mohammad, Maartje Los, Marije Slingerland, Geke A.P. Hospers, Annemieke Cats, Laurens V. Beerepoot, Maarten F. Bijlsma, Hanneke W.M. van Laarhoven
Publikováno v:
Translational Oncology, Vol 49, Iss , Pp 102079- (2024)
Background: HER2 targeting in esophageal adenocarcinoma (EAC) has shown potential, but often fails to show durable response. Given the contributions of the tumor immune microenvironment (TIME) to therapeutic responses, we aimed to chart the TIME char
Externí odkaz:
https://doaj.org/article/140bcec5bc5649c49d43672c34967d9a
Autor:
Esther N. Pijnappel, Melinda Schuurman, Anna D. Wagner, Judith de Vos-Geelen, Lydia G. M. van der Geest, Jan-Willem B. de Groot, Bas Groot Koerkamp, Ignace H. J. T. de Hingh, Marjolein Y. V. Homs, Geert-Jan Creemers, Geert A. Cirkel, Hjalmar C. van Santvoort, Olivier R. Busch, Marc G. Besselink, Casper H.J. van Eijck, Johanna W. Wilmink, Hanneke W. M. van Laarhoven
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundBiological sex, gender and age have an impact on the incidence and outcome in patients with metastatic pancreatic cancer. The aim of this study is to investigate whether biological sex, gender and age are associated with treatment allocatio
Externí odkaz:
https://doaj.org/article/4f79caf484fb429aad6b52f77ca218c8
Autor:
Sophie Kurk, Petra Peeters, Rebecca Stellato, B. Dorresteijn, Pim deJong, Marion Jourdan, Geert‐Jan Creemers, Frans Erdkamp, Felix deJongh, Peter Kint, Lieke Simkens, Bea Tanis, Manuel Tjin‐A‐Ton, Ankie Van Der Velden, Cornelis Punt, Miriam Koopman, Anne May
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 4, Pp 803-813 (2019)
Abstract Background Increasing evidence suggests that severe skeletal muscle index (SMI) loss (sarcopenia) is associated with poor overall survival in metastatic colorectal cancer patients, but its mechanisms are unknown. We recently found, using dat
Externí odkaz:
https://doaj.org/article/3d5c77737151488faf4682ef3ab94d0f
Autor:
Anieta M. Sieuwerts, Wendy Onstenk, Jaco Kraan, Corine M. Beaufort, Mai Van, Bram De Laere, Luc Y. Dirix, Paul Hamberg, Aart Beeker, Hielke J. Meulenbeld, Geert‐Jan Creemers, Wytske M. vanWeerden, Guido W. Jenster, Annemieke J. M. Nieuweboer, Ron H. J. Mathijssen, Ronald deWit, John W. M. Martens, Stefan Sleijfer
Publikováno v:
Molecular Oncology, Vol 13, Iss 8, Pp 1795-1807 (2019)
The androgen receptor splice variant (AR‐V) 7 in circulating tumor cells (CTCs) is a predictor for resistance to anti‐AR‐targeted treatment, but not to taxane‐based chemotherapy in metastatic castration‐resistant prostate cancer (mCRPC). In
Externí odkaz:
https://doaj.org/article/9ca2c96fafc6462f975ce13bf278760c
Publikováno v:
Case Reports in Oncology, Vol 11, Iss 3, Pp 654-659 (2018)
Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents. We present a case with terminal ileitis as a rar
Externí odkaz:
https://doaj.org/article/31c347b3b1f84adf9a18385426ada793
Autor:
Irma C. Noordzij, Wouter L. Curvers, Clément J. Huysentruyt, Grard A.P. Nieuwenhuijzen, Geert-Jan Creemers, Maurice J.C. van der Sangen, Erik J. Schoon
Publikováno v:
Endoscopy International Open, Vol 06, Iss 09, Pp E1126-E1129 (2018)
Background and study aims For early esophageal adenocarcinoma, endoscopic resection is an accepted curative treatment with an excellent long-term prognosis. Case series from Japan have reported endoscopic resection of residual esophageal squamous cel
Externí odkaz:
https://doaj.org/article/03c81d1def0e43908780ac6bcada9665
Autor:
Niels A. D. Guchelaar, Bo J. Noordman, Stijn L. W. Koolen, Bianca Mostert, Eva V. E. Madsen, Jacobus W. A. Burger, Alexandra R. M. Brandt-Kerkhof, Geert-Jan Creemers, Ignace H. J. T. de Hingh, Misha Luyer, Sander Bins, Esther van Meerten, Sjoerd M. Lagarde, Cornelis Verhoef, Bas P. L. Wijnhoven, Ron. H. J. Mathijssen
Publikováno v:
Drugs, 83(2), 159-180. Adis
Malignancies of the peritoneal cavity are associated with a dismal prognosis. Systemic chemotherapy is the gold standard for patients with unresectable peritoneal disease, but its intraperitoneal effect is hampered by the peritoneal-plasma barrier. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cebd8e4086bfc35d390fbbafcf04f1e
https://doi.org/10.1007/s40265-022-01828-7
https://doi.org/10.1007/s40265-022-01828-7
Autor:
Cornelis J.A. Punt, Johannes J.M. Kwakman, Linda Mol, Jeanine Roodhart, Mathijs Hendriks, Frank Speetjens, Liselot van Iersel, Marija Trajkovic-Vidakovic, Leontine Spierings, Helgi Helgason, Geert-Jan Creemers, Jan Willem de Groot, Joyce van Dodewaard-de Jong, Maartje Los, Rutger Koornstra, Arnold Baars, Miriam Koopman, Geraldine Vink
Publikováno v:
Clinical colorectal cancer, 21(3), 229-235. Elsevier
Clinical Colorectal Cancer, 21(3), 229-235. CIG Media Group, L.P.
Clinical Colorectal Cancer, 21(3), 229-235. CIG Media Group, L.P.
INTRODUCTION: The oral fluoropyrimidine S-1 has shown comparable efficacy to capecitabine in Asian and some Western studies on metastatic colorectal cancer. S-1 is associated with a lower incidence of hand-foot syndrome (HFS) and cardiac toxicity. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1814d16384a7e141c8e9928d029e0e98
https://cris.maastrichtuniversity.nl/en/publications/4488cfe8-33bc-43e1-9cf1-cec5e5fb3f7d
https://cris.maastrichtuniversity.nl/en/publications/4488cfe8-33bc-43e1-9cf1-cec5e5fb3f7d
Autor:
Patricia A.H. Hamers, Geraldine R. Vink, Marloes A.G. Elferink, Rebecca K. Stellato, Willemieke P.M. Dijksterhuis, Cornelis J.A. Punt, Miriam Koopman, Anne M. May, Laurens V. Beerepoot, Geert-Jan Creemers, Hester van Cruijsen, Jan Willem B. de Groot, Henk K. van Halteren, Helgi H. Helgason, Mathijs P. Hendriks, Ronald Hoekstra, Lieke H. van Huis-Tanja, Ellen Kapiteijn, Maartje Los, Esther van Meerten, Natascha A.J.B. Peters, Johannes F.M. Pruijt, Patricia Quarles van Ufford-Mannesse, Mark P.S. Sie, Dirkje W. Sommeijer, Leontine E.A.M.M. Spierings, Frederiek Terheggen, Manuel L.R. Tjin-A-Ton, Liselot B.J. Valkenburg-van Iersel, Theo van Voorthuizen, Judith de Vos-Geelen, Annelie J.E. Vulink, Agnès J van de Wouw
Publikováno v:
Clinical Colorectal Cancer, 21(2), 154-166. Elsevier
on behalf of the QUALITAS study group 2022, ' Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS) ', Clinical Colorectal Cancer, vol. 21, no. 2, pp. 154-166 . https://doi.org/10.1016/j.clcc.2022.03.002
Clinical colorectal cancer, 21(2), 154-166. Elsevier
Clinical Colorectal Cancer, 21(2), 154-166. CIG Media Group, L.P.
on behalf of the QUALITAS study group 2022, ' Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS) ', Clinical Colorectal Cancer, vol. 21, no. 2, pp. 154-166 . https://doi.org/10.1016/j.clcc.2022.03.002
Clinical colorectal cancer, 21(2), 154-166. Elsevier
Clinical Colorectal Cancer, 21(2), 154-166. CIG Media Group, L.P.
INTRODUCTION: The RECOURSE trial demonstrated a modest benefit in overall survival (OS) for trifluridine/tipiracil (FTD/TPI) versus placebo in pretreated metastatic colorectal cancer (mCRC) patients. Unfortunately, quality of life (QoL) was not asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8074c3f95e3d5c5234a7fcca8125ae85
https://doi.org/10.1016/j.clcc.2022.03.002
https://doi.org/10.1016/j.clcc.2022.03.002